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Abstract  
BACKGROUND: Neonatal jaundice that occurs in ABO or Rhesus issoimunisation has been 
recognized as one of the major risk factors for development of severe hyperbilirubinemia and 
bilirubin neurotoxicity. 
AIM: Aim of our study was to investigate clinical and laboratory parameters associated with 
hemolytic jaundice due to Rh and ABO incompatibility and compare results with the group of 
unspecific jaundice. 
MATERIAL AND METHODS: One hundred sixty seven (167) neonatal hyperbilirubinemia cases 
were included in the study, 24.6% of which presented with ABO/Rhesus type hemolytic jaundice, 
and the rest with unspecific jaundice. Evaluation included: blood count, reticulocites, serum 
bilirubin, aminotransferases, blood grouping, and Coombs test, also the day of bilirubin peak, 
duration of the hyperbilirubinemia, and additional bilirubin measurements. 
RESULTS: We showed significantly lower mean values of hemoglobin, erythrocytes and hematocrit 
and significantly higher values of reticulocytes in the group of ABO/Rh incompatibility compared to 
the group of jaundice of unspecific etiology; also an earlier presentation and a higher-grade 
jaundice in this group.  
CONCLUSIONS: The laboratory profile in ABO/Rh isoimmunisation cases depicts hemolytic 
mechanism of jaundice. These cases carry a significant risk for early and severe hyperbilirubinemia 
and are eligible for neurodevelopmental follow-up. Hematological parameters and blood grouping 
are simple diagnostic methods that assist the etiological diagnosis of neonatal hyperbilirubinemia. 
 
 
 
 
Introduction 
 
Neonatal jaundice is a common phenomenon 
during the first week of postnatal life affecting almost 
two thirds of term newborns [1, 2]. The mechanism of 
neonatal hyperbilirubinemia is multifactorial, 
comprising primarily processes that contribute to 
increased bilirubin load, or diminished bilirubin 
clearance [1-3]. The former may result from causes 
that potentiate bilirubin production and the 
enterohepatic circulation, whereas the latter may 
result from immature conjugative capacity, and/or 
impaired hepatic uptake or excretion [1-3]. It has been 
shown that the imbalance between bilirubin production 
and conjugation plays an important role in the 
mechanism of neonatal bilirubinemia [4]. Although 
both genetic and environmental factors may contribute 
to the development of neonatal hyperbilirubinemia, the 
importance of genetically determined conditions has 
been increasingly recognized [5-8].  
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Bilirubin overproduction that occurs in ABO, 
Rhesus or minor blood group incompatibilities with a 
positive direct antiglobulin test has been recognized 
as one of the major risk factors for development of 
severe hyperbilirubinemia in infants of 35 or more 
weeks’ gestation [9]. Isoimmune hemolytic disease 
has been included in the ”neurotoxicity risk factors‟ list 
aimed to emphasizing main risk factors associated 
with brain damage in severe hyperbilirubinemia [10]. 
Lower phototherapy and exchange transfusion 
threshold levels are recommended in isoimmune 
hemolytic disease in order to prevent acute 
manifestations of bilirubin toxicity that might evolve 
into chronic and permanent neurological sequelae- 
kernicterus. Features of the latter include athetoid 
cerebral palsy, hearing loss, and intellectual 
handicaps, visual and dental problems [1-3, 9-11].  
In a previous study we showed a prevalence 
of 14.43% of hemolysis in a group of infants with 
indirect hyperbilirubinemia in a two-year period. We 
also showed a high prevalence (44.37%) of jaundice 
of unidentified etiology; the group included: 
exaggerated physiological jaundice, early and late 
onset breast-milk jaundice, and no identifiable etiology 
[12]. 
The aim of our study was to investigate 
clinical and laboratory parameters associated with 
hemolytic jaundice due to Rh and ABO incompatibility 
and compare results with the group of unspecific 
jaundice with unidentifiable etiology.  
 
 
Material and Methods  
 
The study group included 167 newborns 
treated with neonatal hyperbilirubinemia at the 
University Pediatric Clinic’s Neonatology Department 
in Skopje, Republic of Macedonia; 41 patient (24.6%) 
who presented with ABO or Rhesus type hemolytic 
disease of the newborn, and 126 patients (75.4%) 
who were treated with unspecific neonatal jaundice 
(Table 1). Medical records were reviewed extensively 
to exclude clinical signs and symptoms that could 
increase the extent of jaundice such as: 
cephalhaemathoma, bruising, ecchymoses, 
lacerations, sepsis, prematurity, hypothyroidism, CNS 
hemorrhage, intestinal atresia or stenosis, 
hypertrophyc pyloric stenosis, delayed meconium 
passage, G6PD deficiency and Down syndrome [3, 
12, 13]. The following laboratory tests were 
performed: full blood count and smear, hemoglobin 
and hematocrit levels, reticulocite count, serum levels 
of total, indirect and direct bilirubin, serum 
aminotransferases- aspartat transaminase (AST) and 
alanin transaminase (ALT), glucose-6-phosphate 
dehydrogenase (G6PD) quantitative test, maternal 
and neonatal blood groups, direct antiglobulin 
(Coombs) test. The study also included evaluation of 
the day at which bilirubin level reached peak, duration 
of the hyperbilirubinemia, as well as the first and 
second control bilirubin measurement where clinically 
indicated. In some cases, tests such as C-reactive 
protein (CRP), blood, cerebrospinal fluid and other 
cultures, thyroid function tests as well as 
ultrasonography of the central nervous system and 
radiograms were performed to exclude other 
etiologies of jaundice [1-3, 9, 11-13]. Hemolytic 
etiology of jaundice was considered in cases of 
Coombs positive ABO or Rh blood group 
incompatibility. Undefined etiology of jaundice was 
defined as previously described [12]. 
Full blood count was analyzed using the 
Sysmex K-4500 automated hematology analyzer 
(Minesota, USA); light microscopy was involved when 
analyzing blood smear and reticulocites. Total serum 
bilirubin and fractions were obtained using 
photometric chemistry analyzer Kodak Ectachem 250 
(Rochester, NY) [14]. G6PD activity in erythrocytes 
was determined spectrophotometricaly. The rate of 
absorbance change was measured at 340 nm, due to 
the reduction of nicotinamide adenine dinucleotide 
phosphate (NADP) to NADPH when a sample was 
incubated with G6P (Humananalyser 3000, Germany). 
G6PD activity was calculated in relation to erythrocyte 
count. Commercially available kits (AMS U.K. Ltd, 
East Sussex, U.K.) were used. Values of 272±27 
mU/10
9
 erythrocytes were considered normal, and 
results were interpreted as percentage of the normal 
G6PD activity [15, 16]. 
Statistical analyses were performed using the 
statistical package Statistical Package for the Social 
Sciences (SPSS) 17.0 for Windows (SPSS Inc., 
Chicago, IL, USA). Categorical variables were 
presented with absolute numbers and percentages 
whereas quantitative variables were presented with 
mean, standard deviation, minimum, maximum, 
median and rang. Testing of significance between 
groups regarding the analyzed parameters was 
performed with: Student t-test, and Mann-Whitney U 
test. The result was considered significant if 
probability value (p) was <0.05 and <0.01 for high 
significance. The study has been approved by an 
institutional Ethics Committee in accordance with the 
Declaration of Helsinki. 
 
 
Results 
 
The subject group consisted of 167 patients 
with indirect neonatal hyperbilirubinemia including 41 
patients (24.6%) with ABO or Rhesus type hemolytic 
disease of the newborn, and 126 patients (75.4%) 
with unspecific neonatal jaundice (Table 1).  
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Table 1: Study group 
 Etiology group Number of patients Percentage (%) 
1.  Hemolysis (ABO and Rh incompatibility) 41 24.6 
2. Unspecific jaundice 126 75.4 
 Total 167 100 
 
Laboratory parameters that were analyzed 
from full blood count were: 1) Hemoglobin (Hb), 2) 
Erythrocytes (Er), and 3) Hematocrit (Hct). 
In the group of newborns with ABO/Rh 
incompatibility significantly lower mean values of 
hemoglobin (p = 0.038), erythrocytes (p = 0.0023) and 
hematocrit (p = 0.037) were noted compared to the 
group of jaundice with unspecific etiology (Table 2). 
Table 2: Analyses from full blood count 
Groups Descriptive Statistics  
N mean±SD min-max t-value , p 
Hb (g/l) 
1. 41 155.02 ± 30.3 74  - 218 t=2.09   p=0.038* 
2. 126 165.36 ± 26.5 105 - 224 
Er (x10
12
) 
1. 41 4.29 ± 0.8 2.05 – 5.81 t=3.09 p=0.0023* 
2. 126 4.67 ± 0.6 3.27 – 6.58 
Htc (%) 
1. 41 41.35 ± 8.9 18.9 – 61.9 t=2.11   p=0.037* 
2. 126 44.26 ± 7.2 28.4 – 64.6 
     
*p < 0.05; t- Student t test; N- number of patients; SD- standard deviation; p- probability 
value. 
 
Mean reticulocyte count was highly 
significantly higher (p = 0.000036) in the group of 
ABO/Rh incompatibility (27.88 ± 26.4 vs. 11.94 ± 7.4). 
In this group of newborns, the jaundice appeared 
significantly earlier (p < 0.01) compared to the group 
of jaundice with unidentified etiology (2.63 ± 2.4 vs. 
4.02 ± 2.5 days). Duration of the bilirubin peak was 
significantly longer (p = 0.036) in the group of 
unspecific jaundice (15.03 ± 25.7 vs. 10.22 ± 9.02 
days) (Table 3). 
Table 3: Analyses of bilirubin 
Groups Descriptive Statistics  
N mean±SD median min-max t-value, p 
Ret 
1. 41 27.88 ± 26.4 22.0 2 - 121 Z=4.13 
p=0.000036** 2. 126 11.94 ± 7.4 11.0 1 - 39 
Day of bilirubin peak 
1. 41 2.63 ± 2.4 2.0 1 – 14 Z=5.78 
p=0.000** 2. 126 4.02 ± 2.5 3.0 2 – 14 
Peak bilirubin level (μmol/l) 
1. 41 379.76 ± 133.5 364.0 158 – 801 Z=1.95 
p=0.052 NS 2. 126 333.44 ± 91.1 324.0 107 - 598 
Duration of the bilirubin peak (days) 
1. 41 10.22 ± 9.02 6.0 1 – 37 Z=2.09 
p=0.036* 2. 126 15.03 ± 25.7 9.0 2 - 279 
First control bilirubin (μmol/l) 
1. 40 274.2 ± 124.9 235.5 96 – 682 Z=1.87 
p=0.062 NS 2. 112 227.39 ± 80.7 211.5 60 - 473 
Second control bilirubin (μmol/l) 
1. 24 227.46 ± 83.4 206.0 111 – 437 Z=0.76 
p=0.448 NS 2. 48 221.92 ± 48.3 228.5 51 - 314 
      
*p < 0.05;   **p<0,01  Z (Mann-Whitney U test); N- number of patients; SD- standard 
deviation; p- probability value; NS- not significant. 
 
Newborns from the ABO/Rh incompatibility 
group compared to the group of newborns with 
unspecific jaundice had insignificantly higher peak 
bilirubin level (p = 0.052), as well as insignificantly 
higher levels at the first (p = 0.062) and second 
(p=0.448) control bilirubin measurements (Table 3).  
Levels of hepatic transaminases (AST and 
ALT) were not found to depend significantly on the 
etiology of jaundice (Table 4).  
Table 4: Amynotransferases- AST and ALT 
Groups Descriptive Statistics  
N mean±SD median min-max t-value , p 
AST (U/l) 
1. 41 62.51 ± 47.8 51.0 22 – 317 Z=0.067 
p=0.95 NS 2. 125 58.62 ± 32.2 52.0 21 - 218 
ALT (U/l) 
1. 41 33.09 ± 23.5 28 3 – 109 Z=0.19 
p=0.85 NS 2. 125 32.27 ± 24.5 30 3 - 170 
Z (Mann-Whitney U test); N- number of patients; SD- standard deviation; p- probability 
value; NS- not significant. 
 
Treatment of jaundice was performed 
according to current protocols with continuous 
phototherapy/ and or exchange transfusion [1, 3, 9, 
17-21]. The bulk of the cases 161 (96.4%) were 
managed conventionally using double surface blue 
light phototherapy lamps at wave length of 460 nm. 
Six patients (3.6% of the whole group, and 14.6% of 
the hemolytic etiology group) were treated with 
exchange transfusion (ECT) out of which 4 (two 
thirds) patients presented with ABO incompatibility, 
and the remaining 2 with Rh incompatibility.  
 
 
Discussion  
 
In this study we aimed to investigate clinical 
and laboratory parameters associated with hemolytic 
jaundice due to Rh and ABO incompatibility and 
compare results with a group of infants with jaundice 
of unspecific origin. We proved statistically significant 
correlations of all relevant laboratory parameters 
between the two groups. In a previous study, we 
found a high prevalence of jaundice of undefined 
etiology (44.37%), ascribed to cases where despite 
intensive workout, no identifiable cause or contributing 
factor for jaundice could be found [12]. We speculated 
an imbalance between bilirubin production and 
conjugation to be the key concept of jaundice in this 
group based on lack of history, clinical and laboratory 
data that would indicate another mechanism of 
jaundice [4, 12]. This group was used as a reference 
for comparison of clinical and laboratory parameters. 
Blood group incompatibility induced haemolysis 
(either ABO or Rh) has been identified as one of the 
risk factor for both severe hyperbilirubinemia and 
bilirubin neurotoxicity in infants of 35 or more weeks’ 
gestation [9, 10]. Moreover, it has been postulated 
that synergistic effect of DAT positive isoimmune 
hemolytic disease and severe hyperbilirubinemia 
potentiate bilirubin-induced neurotoxicity [22]. Lower 
phototherapy and exchange transfusion threshold 
levels have been recommended in isoimmune 
hemolytic disease to prevent manifestations of 
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bilirubin encephalopathy, also a pre-discharge risk 
assessment and early post-discharge follow up [9, 10, 
17-19]. In a Turkish study, 19 out of 93 (20.43%) 
extreme hyperbilirubinemia patients were 
isoimmunised [23]. In two other studies ABO 
isoimmunization was reported as the most common 
cause of hyperbilirubinemia requiring ECT, reported 
rates were 38% and 27.8% respectively [24, 25]. ECT 
was performed in 14.6% of our isoimmunisation 
cases, 66.6% of which were attributable to ABO 
incompatibility, and the rest to Rh incompatibility. We 
included only Coombs positive cases in our study to 
avoid uncertainty in interpreting etiology. We did not 
include any G6PD deficient cases in the group of 
hemolytic etiology for the same reason. Although 
G6PD deficiency associated neonatal 
hyperbilirubinemia was traditionally considered 
hemolytic in origin, it was shown that inadequate 
bilirubin conjugation in the liver was the key 
component of neonatal jaundice in these patients [26, 
27]. We found significantly lower mean values of 
hemoglobin, erythrocytes and hematocrit and highly 
significantly higher values of reticulocytes in the group 
of ABO/Rh incompatibility compared to the group of 
jaundice of unspecific etiology. This confirms that 
hemolysis is the main component of jaundice in this 
group of patients and is consistent with findings from 
other studies [13, 28]. In this group of newborns, the 
jaundice appeared significantly earlier compared to 
the group of jaundice with unidentified etiology (at 
median age of 2 days). Although peak bilirubin level in 
the hemolytic group was insignificantly higher 
compared to the other group, a clear tendency to 
earlier rise and higher values of serum bilirubin were 
noted. Duration of the bilirubin peak was significantly 
longer in the group of unspecific jaundice. We can 
speculate that this finding might reflect differences in 
response to phototherapy in both groups, 
nevertheless, other impacts such as different 
mechanisms of jaundice, dissimilar biological progress 
of jaundice or stringency to phototherapy cannot be 
excluded. Levels of hepatic transaminases (AST and 
ALT) were not found to depend significantly on the 
etiology of jaundice. Although analysis of 
transaminases is performed on a regular basis in our 
hospital practices when evaluating an infant for 
jaundice, it is of little clinical value in cases of 
unconjugated hyperbilirubinemia and cannot be 
readily recommended. According to an evidence-
based review on neonatal hyperbilirubinemia, the 
majority of kernicterus cases occurred in infants with a 
bilirubin level higher than 20 mg/dL (342 umol/l) [29]. 
It is clear that our hemolysis cases with mean peak 
bilirubin levels of 379.8 ± 133.5 umol/l are eligible for 
the neurotoxic effects of the high bilirubinemia 
especially the ones towards the higher end of the 
spectrum (maximum of 801 umol/l) and are 
candidates for long-term neurodevelopmental follow-
up. Therefore, clinicians’ awareness of potential treats 
and harms that might be associated with 
isoimmunisation is vital.  
In conclusion, aboratory profile in ABO and 
Rh isoimmunisation cases depicts hemolytic 
mechanism of jaundice. This group of patients is 
associated with a significant risk for early and severe 
hyperbilirubinemia and is eligible for long-term 
neurodevelopmental follow-up. Hematological 
parameters together with blood grouping are simple 
diagnostic methods that assist the etiological 
diagnosis of neonatal hyperbilirubinemia. 
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